

**Strategies to Reduce Morbidity and Mortality in COPD:
A Patient-focused Approach for Integration of Combination and Triple Therapy
Tweeterial #3 References**

Tweet 3

Global Initiative for Chronic Obstructive Lung Disease (GOLD): global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; 2020. www.goldcopd.org/gold-reports

Tweet 4

Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official american thoracic society clinical practice guideline. *Am J Respir Crit Care Med*. 2020;201(9):e56-e69. <https://doi.org/10.1164/rccm.202003-0625ST>

Tweet 6

Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. *Respir Res*. 2019;20(1):238. <https://doi.org/10.1186/s12931-019-1193-9>

Tweet 7

Global Initiative for Chronic Obstructive Lung Disease (GOLD): global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; 2020. www.goldcopd.org/gold-reports

Tweet 10

Global Initiative for Chronic Obstructive Lung Disease (GOLD): global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; 2020. www.goldcopd.org/gold-reports

Tweet 13

Global Initiative for Chronic Obstructive Lung Disease (GOLD): global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; 2020. www.goldcopd.org/gold-reports

CAT, COPD assessment test
COPD, chronic obstructive pulmonary disorder
Diff, different
Eos, eosinophils
FEV1, forced expiratory volume
FVC, forced vital capacity
ICS, inhaled corticosteroids
LABA, long-acting-beta-agonists
LAMA, long-acting muscarinic antagonists
Mechs, mechanisms
Tx, treatment
Vs, versus